These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8987977)

  • 1. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.
    Tsiang M; Paborsky LR; Li WX; Jain AK; Mao CT; Dunn KE; Lee DW; Matsumura SY; Matteucci MD; Coutré SE; Leung LL; Gibbs CS
    Biochemistry; 1996 Dec; 35(51):16449-57. PubMed ID: 8987977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of thrombin into an anticoagulant by protein engineering.
    Gibbs CS; Coutré SE; Tsiang M; Li WX; Jain AK; Dunn KE; Law VS; Mao CT; Matsumura SY; Mejza SJ
    Nature; 1995 Nov; 378(6555):413-6. PubMed ID: 7477382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of thrombin's procoagulant and anticoagulant properties.
    Leung LL; Gibbs CS
    Thromb Haemost; 1997 Jul; 78(1):577-80. PubMed ID: 9198219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Leu99 of thrombin in determining the P2 specificity of serpins.
    Rezaie AR
    Biochemistry; 1997 Jun; 36(24):7437-46. PubMed ID: 9200692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational engineering of activity and specificity in a serine protease.
    Dang QD; Guinto ER; di Cera E
    Nat Biotechnol; 1997 Feb; 15(2):146-9. PubMed ID: 9035139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombin: a multifunctional enzyme].
    Polack B
    Ann Biol Clin (Paris); 2003; 61(1):23-31. PubMed ID: 12604383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical modification of alpha-thrombin and in vitro characterization of its anticoagulant activity.
    Nakagomi K; Ajisaka K
    Biochem Int; 1990 Oct; 22(1):75-84. PubMed ID: 2177988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidation of human alpha-thrombin by the myeloperoxidase-H2O2-chloride system: structural and functional effects.
    De Cristofaro R; Landolfi R
    Thromb Haemost; 2000 Feb; 83(2):253-61. PubMed ID: 10739383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant.
    Richardson MA; Gerlitz B; Grinnell BW
    Nature; 1992 Nov; 360(6401):261-4. PubMed ID: 1436107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of lysine 60f to S1' specificity of thrombin.
    Rezaie AR; Olson ST
    Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies.
    Membre A; Wahl D; Latger-Cannard V; Max JP; Lacolley P; Lecompte T; Regnault V
    Haematologica; 2008 Apr; 93(4):566-73. PubMed ID: 18322249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
    J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
    Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs.
    Leung LL
    Thromb Haemost; 1995 Jul; 74(1):373-6. PubMed ID: 8578488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.
    Berg DT; Gerlitz B; Shang J; Smith T; Santa P; Richardson MA; Kurz KD; Grinnell BW; Mace K; Jones BE
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4423-8. PubMed ID: 12671072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
    Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
    Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of platelet contractile force as a research and clinical measure of platelet function.
    Carr ME
    Cell Biochem Biophys; 2003; 38(1):55-78. PubMed ID: 12663942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock.
    Tsen A; Kirschenbaum LA; LaRow C; Khan R; Kurtz S; Bansal S; Astiz ME
    Shock; 2009 Feb; 31(2):120-4. PubMed ID: 18636042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.